NSF/FDA SIR: Isolation of Cancer Stem Cells by Flow Cytometric Techniques

NSF/FDA SIR：通过流式细胞术技术分离癌症干细胞

• 批准号: 1238375
• 负责人: Elizabeth Raveche
• 金额: $ 11.45万
• 依托单位: Rutgers, The State University of New Jersey-RBHS-New Jersey Med
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-06-15 至 2013-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1238375&HistoricalAwards=false
• 关键词: NSF; FDA; SIR; Isolation; Cancer

ABSTRACT #1238375RavecheThe major objective of the proposed research is to employ advanced flow-cytometry-based instrumentation to develop methods and protocols for isolating distinct subpopulations of cells. This in-depth analysis of cell characterizations using fluorescence detection to distinguish 17 or more characteristics simultaneously on individual cells and employing multiple parameters to sort these populations while maintaining the viability of the cells will advance the employment of flow cytometers in biomedical research. The isolation and identification of the cancer progenitor cell is only recently feasible because the technology has evolved such that multiple fluorochromes excited by specific wavelengths emitted from several lasers and unique detectors can sort cells based on multiple markers simultaneously. This requires stable laser lines, careful compensation controls, defined fluidics and sensitive optics and detectors. The hypothesis to be tested is that based on identifiable characteristics, the earliest cancer progenitor cell in chronic lymphocytic leukemia (CLL) can be identified.

摘要#1238375 Raveche拟议研究的主要目标是采用先进的基于流式细胞术的仪器来开发分离不同细胞亚群的方法和方案。这种对细胞特征的深入分析使用荧光检测来同时区分单个细胞上的17个或更多特征，并采用多个参数来对这些群体进行分类，同时保持细胞的活力，这将促进流式细胞仪在生物医学研究中的应用。癌症祖细胞的分离和鉴定直到最近才可行，因为该技术已经发展到由几个激光器和独特的检测器发射的特定波长激发的多种荧光染料可以同时基于多种标记物对细胞进行分选。这需要稳定的激光线，仔细的补偿控制，定义的射流和敏感的光学和检测器。待检验的假设是，基于可识别的特征，可以识别慢性淋巴细胞白血病（CLL）中最早的癌症祖细胞。